BriaCell Therapeutics Corp
BCT
Company Profile
Business description
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company’s targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.
Contact
235-15th Street
Suite 300, 3rd Floor, Bellevue Centre
West Vancouver
VancouverBCV7T 2X1
CANT: +1 888 485-6340
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 July 2026
Employees
4
Stocks News & Analysis
stocks
Cheap e-commerce share continues sales momentum
The e-commerce business continues its sales momentum despite challenging backdrop.
stocks
Chart of the Week: Booming mined commodity prices see little value on offer
Iran War disruptions drive thermal coal and aluminum prices higher but value to be found in other pockets.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,819.60 | 65.10 | -0.73% |
| CAC 40 | 8,177.11 | 30.78 | -0.38% |
| DAX 40 | 25,151.14 | 26.66 | -0.11% |
| Dow JONES (US) | 50,644.28 | 182.60 | 0.36% |
| FTSE 100 | 10,416.16 | 88.85 | -0.85% |
| HKSE | 25,003.25 | 324.98 | -1.28% |
| NASDAQ | 26,674.73 | 18.55 | 0.07% |
| Nikkei 225 | 64,693.12 | 306.29 | -0.47% |
| NZX 50 Index | 13,206.11 | 21.70 | -0.16% |
| S&P 500 | 7,520.36 | 1.24 | 0.02% |
| S&P/ASX 200 | 8,592.90 | 61.60 | -0.71% |
| SSE Composite Index | 4,098.64 | 4.91 | 0.12% |